BI opens up data files
Boehringer Ingelheim announced Monday that it will make clinical study data accessible once a drug has been approved or a drug development program has been terminated.
The company said in a statement Monday that researchers will be able to request de-identified patient data and will receive information if an independent third-party review panel approves the study proposal. BI will redact the information.
The data repository will go back to 1998.